Rosacea is thought to affect around 5% of the global population. Credit: Alona Siniehina / Shutterstock. The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand ...

The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release capsules) for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. In ...

Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. The drug was cleared to treat inflammatory lesions of ...

(RTTNews) - Journey Medical (DERM) announced the FDA has approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's ...